VETO Stock Overview
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VETO from our risk checks.
Vetoquinol SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €97.70 |
| 52 Week High | €110.00 |
| 52 Week Low | €76.30 |
| Beta | 0.91 |
| 1 Month Change | -2.88% |
| 3 Month Change | -10.37% |
| 1 Year Change | 12.04% |
| 3 Year Change | -11.98% |
| 5 Year Change | 75.09% |
| Change since IPO | 324.78% |
Recent News & Updates
Here's What Analysts Are Forecasting For Vetoquinol SA (EPA:VETO) After Its Annual Results
Mar 24
With EPS Growth And More, Vetoquinol (EPA:VETO) Makes An Interesting Case
Jan 13Vetoquinol SA (EPA:VETO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Dec 19Recent updates
Here's What Analysts Are Forecasting For Vetoquinol SA (EPA:VETO) After Its Annual Results
Mar 24With EPS Growth And More, Vetoquinol (EPA:VETO) Makes An Interesting Case
Jan 13Vetoquinol SA (EPA:VETO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Dec 19Vetoquinol (EPA:VETO) Seems To Use Debt Quite Sensibly
Nov 23Here's Why We Think Vetoquinol (EPA:VETO) Is Well Worth Watching
Oct 06Is Vetoquinol SA (EPA:VETO) Trading At A 45% Discount?
Sep 12Are Investors Undervaluing Vetoquinol SA (EPA:VETO) By 28%?
May 24Is Vetoquinol (EPA:VETO) Using Too Much Debt?
May 03Vetoquinol SA (EPA:VETO) Shares Could Be 22% Below Their Intrinsic Value Estimate
Jan 05Here's Why Vetoquinol (EPA:VETO) Has Caught The Eye Of Investors
Dec 01We Think Vetoquinol (EPA:VETO) Can Stay On Top Of Its Debt
Oct 07Vetoquinol SA (EPA:VETO) Shares Could Be 31% Below Their Intrinsic Value Estimate
Aug 19Do Vetoquinol's (EPA:VETO) Earnings Warrant Your Attention?
Jul 16Vetoquinol SA (EPA:VETO) Shares Could Be 29% Below Their Intrinsic Value Estimate
May 07I Ran A Stock Scan For Earnings Growth And Vetoquinol (EPA:VETO) Passed With Ease
Apr 06Calculating The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Dec 21Is Vetoquinol (EPA:VETO) Using Too Much Debt?
Nov 29Estimating The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Sep 10Is Vetoquinol (EPA:VETO) A Risky Investment?
Aug 01Is Vetoquinol SA (EPA:VETO) Trading At A 35% Discount?
May 12Vetoquinol SA's (EPA:VETO) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Feb 11A Look At The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Jan 20Vetoquinol (EPA:VETO) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Dec 29How Much Is Vetoquinol SA (EPA:VETO) Paying Its CEO?
Dec 09We Think Vetoquinol's (EPA:VETO) Statutory Profit Might Understate Its Earnings Potential
Nov 18
Shareholder Returns
| VETO | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 0.4% | -0.5% | -0.1% |
| 1Y | 12.0% | -14.0% | 1.3% |
Return vs Industry: VETO exceeded the French Pharmaceuticals industry which returned -14% over the past year.
Return vs Market: VETO exceeded the French Market which returned 1.3% over the past year.
Price Volatility
| VETO volatility | |
|---|---|
| VETO Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: VETO has not had significant price volatility in the past 3 months.
Volatility Over Time: VETO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 2,497 | Matthieu Frechin | www.vetoquinol.com |
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France.
Vetoquinol SA Fundamentals Summary
| VETO fundamental statistics | |
|---|---|
| Market cap | €1.16b |
| Earnings (TTM) | €55.60m |
| Revenue (TTM) | €529.30m |
20.8x
P/E Ratio2.2x
P/S RatioIs VETO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VETO income statement (TTM) | |
|---|---|
| Revenue | €529.30m |
| Cost of Revenue | €0 |
| Gross Profit | €529.30m |
| Other Expenses | €473.70m |
| Earnings | €55.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 12, 2024
| Earnings per share (EPS) | 4.70 |
| Gross Margin | 100.00% |
| Net Profit Margin | 10.50% |
| Debt/Equity Ratio | 3.1% |
How did VETO perform over the long term?
See historical performance and comparison